BARDA Awards $197M Contract to Vericel for MediWound’s NexoBrid

Event summary

  • BARDA awarded a 10-year contract valued at up to $197M to Vericel for NexoBrid, MediWound’s burn treatment.
  • The base period contract includes $35M, with $10M allocated for initial procurement and VMI establishment.
  • The contract covers procurement, manufacturing facility design, and development of a next-generation formulation.
  • NexoBrid is approved in over 40 countries for enzymatic removal of eschar in burn patients.

The big picture

This contract underscores the strategic importance of NexoBrid in national health preparedness, with BARDA’s investment signaling confidence in the product’s efficacy and scalability. The deal also highlights the growing role of biotech partnerships in addressing critical healthcare needs, particularly in trauma and burn care. With a potential market expansion into blast trauma, MediWound and Vericel could see significant revenue growth and market share gains.

What we're watching

Execution Risk
Whether Vericel can meet the ambitious development and manufacturing milestones under the BARDA contract.
Market Expansion
The pace at which NexoBrid gains traction in the U.S. Strategic National Stockpile and for potential new indications like blast trauma.
Strategic Alignment
How this contract positions MediWound and Vericel in the competitive landscape of burn and wound care treatments.

Related topics

Biotechnology